Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC
Description:
Host: Ghassan K. Abou-Alfa, MD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care...